JP2016522178A5 - - Google Patents

Info

Publication number

JP2016522178A5

JP2016522178A5 JP2016509119A JP2016509119A JP2016522178A5 JP 2016522178 A5 JP2016522178 A5 JP 2016522178A5 JP 2016509119 A JP2016509119 A JP 2016509119A JP 2016509119 A JP2016509119 A JP 2016509119A JP 2016522178 A5 JP2016522178 A5 JP 2016522178A5

Authority

JP

Japan

Prior art keywords

composition

angiotensin

peptide

muscular dystrophy

administered

Prior art date

2014-04-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108010021281 angiotensin I (1-7) Proteins 0.000 claims description 48
• PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims description 21
• 201000006938 muscular dystrophy Diseases 0.000 claims description 19
• 150000001413 amino acids Chemical class 0.000 claims description 17
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
• 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 10
• 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
• 102000001189 Cyclic Peptides Human genes 0.000 claims description 8
• 108010069514 Cyclic Peptides Proteins 0.000 claims description 8
• 210000003205 muscle Anatomy 0.000 claims description 8
• 230000006872 improvement Effects 0.000 claims description 7
• 229940044601 receptor agonist Drugs 0.000 claims description 6
• 239000000018 receptor agonist Substances 0.000 claims description 6
• 101710150190 Beta-secretase 2 Proteins 0.000 claims description 5
• 102100021277 Beta-secretase 2 Human genes 0.000 claims description 5
• 208000035475 disorder Diseases 0.000 claims description 5
• 208000024891 symptom Diseases 0.000 claims description 5
• 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 4
• 201000006793 Walker-Warburg syndrome Diseases 0.000 claims description 4
• 238000007385 chemical modification Methods 0.000 claims description 4
• 238000007918 intramuscular administration Methods 0.000 claims description 4
• 201000000585 muscular atrophy Diseases 0.000 claims description 4
• 229940127264 non-peptide agonist Drugs 0.000 claims description 4
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 4
• 230000019771 cognition Effects 0.000 claims description 3
• 229940079593 drug Drugs 0.000 claims description 3
• 239000003814 drug Substances 0.000 claims description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 2
• 206010069632 Bladder dysfunction Diseases 0.000 claims description 2
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
• 208000032170 Congenital Abnormalities Diseases 0.000 claims description 2
• 208000037141 Congenital muscular dystrophy, Fukuyama type Diseases 0.000 claims description 2
• 206010061619 Deformity Diseases 0.000 claims description 2
• 208000019505 Deglutition disease Diseases 0.000 claims description 2
• 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims description 2
• 201000006813 Fukuyama congenital muscular dystrophy Diseases 0.000 claims description 2
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
• 206010020880 Hypertrophy Diseases 0.000 claims description 2
• 206010061218 Inflammation Diseases 0.000 claims description 2
• 206010023201 Joint contracture Diseases 0.000 claims description 2
• 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims description 2
• 208000036626 Mental retardation Diseases 0.000 claims description 2
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
• 201000001087 Miyoshi muscular dystrophy Diseases 0.000 claims description 2
• 208000009376 Miyoshi myopathy Diseases 0.000 claims description 2
• 208000010428 Muscle Weakness Diseases 0.000 claims description 2
• 206010028289 Muscle atrophy Diseases 0.000 claims description 2
• 206010028372 Muscular weakness Diseases 0.000 claims description 2
• 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
• 108091005804 Peptidases Proteins 0.000 claims description 2
• 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 2
• 239000004365 Protease Substances 0.000 claims description 2
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
• 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 2
• SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims description 2
• 229960000307 avanafil Drugs 0.000 claims description 2
• WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 claims description 2
• 230000006741 behavioral dysfunction Effects 0.000 claims description 2
• 230000015572 biosynthetic process Effects 0.000 claims description 2
• 230000017531 blood circulation Effects 0.000 claims description 2
• 150000001875 compounds Chemical class 0.000 claims description 2
• 239000003246 corticosteroid Substances 0.000 claims description 2
• 230000002950 deficient Effects 0.000 claims description 2
• 230000003111 delayed effect Effects 0.000 claims description 2
• 238000012217 deletion Methods 0.000 claims description 2
• 230000037430 deletion Effects 0.000 claims description 2
• 230000004064 dysfunction Effects 0.000 claims description 2
• 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 2
• 239000000835 fiber Substances 0.000 claims description 2
• 239000012634 fragment Substances 0.000 claims description 2
• 230000004054 inflammatory process Effects 0.000 claims description 2
• 230000005764 inhibitory process Effects 0.000 claims description 2
• 238000003780 insertion Methods 0.000 claims description 2
• 230000037431 insertion Effects 0.000 claims description 2
• 230000000968 intestinal effect Effects 0.000 claims description 2
• 238000001990 intravenous administration Methods 0.000 claims description 2
• 208000028867 ischemia Diseases 0.000 claims description 2
• 108010008097 laminin alpha 2 Proteins 0.000 claims description 2
• 201000010901 lateral sclerosis Diseases 0.000 claims description 2
• 208000005264 motor neuron disease Diseases 0.000 claims description 2
• 230000009756 muscle regeneration Effects 0.000 claims description 2
• 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 claims description 2
• 238000007911 parenteral administration Methods 0.000 claims description 2
• 230000006320 pegylation Effects 0.000 claims description 2
• 208000005987 polymyositis Diseases 0.000 claims description 2
• 230000000241 respiratory effect Effects 0.000 claims description 2
• 150000003839 salts Chemical class 0.000 claims description 2
• 206010039722 scoliosis Diseases 0.000 claims description 2
• 210000002966 serum Anatomy 0.000 claims description 2
• 229960003310 sildenafil Drugs 0.000 claims description 2
• 210000000278 spinal cord Anatomy 0.000 claims description 2
• 238000007920 subcutaneous administration Methods 0.000 claims description 2
• 238000006467 substitution reaction Methods 0.000 claims description 2
• 229960000835 tadalafil Drugs 0.000 claims description 2
• IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims description 2
• 230000000699 topical effect Effects 0.000 claims description 2
• 208000034373 type A muscular dystrophy-dystroglycanopathy Diseases 0.000 claims description 2
• 229960000438 udenafil Drugs 0.000 claims description 2
• IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 claims description 2
• 229960002381 vardenafil Drugs 0.000 claims description 2
• 230000003313 weakening effect Effects 0.000 claims description 2
• 230000003442 weekly effect Effects 0.000 claims description 2
• 229950005371 zaprinast Drugs 0.000 claims description 2
• REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 37
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 230000004199 lung function Effects 0.000 claims 1
• 102000004196 processed proteins & peptides Human genes 0.000 claims 1
• 238000000034 method Methods 0.000 description 39
• 201000010099 disease Diseases 0.000 description 4
• 230000007370 cognitive improvement Effects 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 230000009325 pulmonary function Effects 0.000 description 1